<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Combination beta-lactamase inhibitors, carbapenems, and monobactams
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Combination beta-lactamase inhibitors, carbapenems, and monobactams
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Combination beta-lactamase inhibitors, carbapenems, and monobactams
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Alyssa R Letourneau, MD, MPH
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            David C Hooper, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Keri K Hall, MD, MS
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Nov 13, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         The spectrum of activity and pharmacology of combination beta-lactamase inhibitors, carbapenems, and monobactams will be reviewed here. The mechanisms of action and resistance and major adverse reactions of the beta-lactam antibiotics, issues related to penicillins, and cephalosporins are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/479.html" rel="external">
          "Beta-lactam antibiotics: Mechanisms of action and resistance and adverse effects"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/473.html" rel="external">
          "Penicillin, antistaphylococcal penicillins, and broad-spectrum penicillins"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/480.html" rel="external">
          "Cephalosporins"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          BETA-LACTAMASE INHIBITOR COMBINATIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Clavulanate, sulbactam, tazobactam, avibactam, vaborbactam, relebactam, and durlobactam are beta-lactamase inhibitors that have little intrinsic antibacterial activity but inhibit the activity of a number of plasmid-mediated beta-lactamases [
         <a href="#rid1">
          1-3
         </a>
         ]. Avibactam, vaborbactam, and relebactam inhibit chromosomally mediated AmpC beta-lactamases, and none inhibit the class B metallo-carbapenemases, such as New Delhi metallo-beta-lactamase [
         <a href="#rid2">
          2,4
         </a>
         ]. Combination of one of these agents with
         <a class="drug drug_general" data-topicid="8737" href="/z/d/drug information/8737.html" rel="external">
          ampicillin
         </a>
         ,
         <a class="drug drug_general" data-topicid="8673" href="/z/d/drug information/8673.html" rel="external">
          amoxicillin
         </a>
         ,
         <a class="drug drug_general" data-topicid="9775" href="/z/d/drug information/9775.html" rel="external">
          piperacillin
         </a>
         , ceftolozane,
         <a class="drug drug_general" data-topicid="9226" href="/z/d/drug information/9226.html" rel="external">
          ceftazidime
         </a>
         ,
         <a class="drug drug_general" data-topicid="9613" href="/z/d/drug information/9613.html" rel="external">
          meropenem
         </a>
         , or imipenem-cilastatin results in antibiotics with an enhanced spectrum of activity against many, but not all, organisms containing plasmid-mediated beta-lactamases. The addition of avibactam to ceftazidime, vaborbactam to meropenem, and relebactam to imipenem-cilastatin results in enhanced activity against many, but not all, organisms producing carbapenemases. In addition, sulbactam and tazobactam inhibit the chromosomal beta-lactamase of many
         <em>
          Bacteroides
         </em>
         species, extending the spectrum of coverage of combinations with these compounds to include
         <em>
          Bacteroides
         </em>
         as well. Durlobactam, a novel diazabicyclooctane beta-lactamase inhibitor, was developed to treat
         <em>
          Acinetobacter
         </em>
         species (in combination with sulbactam) and inhibits Class A, C, and D beta-lactamases [
         <a href="#rid3">
          3
         </a>
         ].
        </p>
        <p>
         Dosing of combination beta-lactam beta-lactamase inhibitors is listed separately, and the dosing should be modified in the setting of renal dysfunction  (
         <a class="graphic graphic_table graphicRef51241" href="/z/d/graphic/51241.html" rel="external">
          table 1
         </a>
         ). For
         <a class="drug drug_general" data-topicid="9777" href="/z/d/drug information/9777.html" rel="external">
          piperacillin-tazobactam
         </a>
         , an extended infusion (eg, 3.375 g infused over four hours every eight hours) is an alternative to standard dosing; in particular, this strategy has been used for critically ill patients or for pathogens with elevated but susceptible-range minimum inhibitory concentrations (MICs). The benefits of extended infusion over standard dosing have been suggested by some studies but not all [
         <a href="#rid5">
          5-7
         </a>
         ]. Overall, this dosing regimen is at least equivalent and may be superior to standard dosing in appropriate patient populations. (See
         <a class="medical medical_review" href="/z/d/html/97446.html" rel="external">
          "Prolonged infusions of beta-lactam antibiotics"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H95654503">
         <span class="h2">
          Amoxicillin-clavulanate
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="8676" href="/z/d/drug information/8676.html" rel="external">
          Amoxicillin-clavulanate
         </a>
         will inhibit most strains of oxacillin-susceptible
         <em>
          Staphylococcus aureus
         </em>
         and beta-lactamase producing
         <em>
          Haemophilus influenzae
         </em>
         in addition to the usual organisms inhibited by
         <a class="drug drug_general" data-topicid="8673" href="/z/d/drug information/8673.html" rel="external">
          amoxicillin
         </a>
         alone (see
         <a class="medical medical_review" href="/z/d/html/473.html" rel="external">
          "Penicillin, antistaphylococcal penicillins, and broad-spectrum penicillins"
         </a>
         ). At the high drug concentrations achieved in urine, the combination is also active against certain beta-lactamase-producing Enterobacterales. Amoxicillin-clavulanate can be used as oral therapy for patients with otitis media, sinusitis, lower respiratory infections, bite wounds, and urinary tract infections [
         <a href="#rid8">
          8
         </a>
         ], although there are no data that this combination is superior to other antibiotics (such as
         <a class="drug drug_general" data-topicid="9785" href="/z/d/drug information/9785.html" rel="external">
          trimethoprim-sulfamethoxazole
         </a>
         or the second or third generation oral cephalosporins). (See
         <a class="medical medical_review" href="/z/d/html/7671.html" rel="external">
          "Animal bites (dogs, cats, and other mammals): Evaluation and management"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H95654485">
         <span class="h2">
          Ampicillin-sulbactam
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="8745" href="/z/d/drug information/8745.html" rel="external">
          Ampicillin-sulbactam
         </a>
         is a parenteral formulation that expands the spectrum of
         <a class="drug drug_general" data-topicid="8737" href="/z/d/drug information/8737.html" rel="external">
          ampicillin
         </a>
         to include most strains of
         <em>
          S. aureus
         </em>
         and beta-lactamase producing
         <em>
          H. influenzae
         </em>
         , some Enterobacterales, and anaerobes (including
         <em>
          Bacteroides fragilis
         </em>
         ). The sulbactam component of ampicillin-sulbactam has activity against many strains of
         <em>
          Acinetobacter baumannii
         </em>
         . Ampicillin-sulbactam has been used to treat patients with diabetic foot ulcers [
         <a href="#rid9">
          9
         </a>
         ]. This combination has also been used for prophylaxis and therapy of intra-abdominal and pelvic infections instead of
         <a class="drug drug_general" data-topicid="9223" href="/z/d/drug information/9223.html" rel="external">
          cefoxitin
         </a>
         . Randomized, double-blind trials showed ampicillin-sulbactam to be equivalent to cefoxitin in prophylaxis for abdominal surgery and in the treatment of intra-abdominal and pelvic infections [
         <a href="#rid10">
          10,11
         </a>
         ]. Increasing resistance worldwide to ampicillin-sulbactam in both Enterobacterales and
         <em>
          B. fragilis
         </em>
         in intra-abdominal infections, however, renders this drug combination less useful for these infections [
         <a href="#rid12">
          12-14
         </a>
         ].
        </p>
        <p>
         In some parts of the world, an oral prodrug of
         <a class="drug drug_general" data-topicid="8745" href="/z/d/drug information/8745.html" rel="external">
          ampicillin-sulbactam
         </a>
         , sultamicillin, is available in tablet form (sultamicillin tosylate) or powder for oral suspension [
         <a href="#rid15">
          15
         </a>
         ]. Sultamicillin has a similar spectrum of activity to ampicillin-sulbactam and has been used for infections of the ear, sinus, throat, lower respiratory tract, urinary tract, female genital tract, skin, and soft tissues [
         <a href="#rid16">
          16,17
         </a>
         ]. The adult dose ranges from 375 to 750 mg two to three times daily and warrants dose reduction in the setting of renal impairment.
        </p>
        <p class="headingAnchor" id="H95654491">
         <span class="h2">
          Piperacillin-tazobactam
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9777" href="/z/d/drug information/9777.html" rel="external">
          Piperacillin-tazobactam
         </a>
         expands the spectrum of
         <a class="drug drug_general" data-topicid="9775" href="/z/d/drug information/9775.html" rel="external">
          piperacillin
         </a>
         to include beta-lactamase producing
         <em>
          S. aureus
         </em>
         ,
         <em>
          H. influenzae
         </em>
         ,
         <em>
          Neisseria gonorrhoeae
         </em>
         , some Enterobacterales, and anaerobes (including
         <em>
          B. fragilis
         </em>
         ) [
         <a href="#rid18">
          18
         </a>
         ]. This combination is generally not effective for piperacillin-resistant strains of
         <em>
          Pseudomonas aeruginosa
         </em>
         .
        </p>
        <p>
         <a class="drug drug_general" data-topicid="9777" href="/z/d/drug information/9777.html" rel="external">
          Piperacillin-tazobactam
         </a>
         should be dosed at 4.5 g every six hours (for normal renal function) to treat susceptible
         <em>
          P. aeruginosa
         </em>
         infections. The increased dose allows for adequate drug concentrations to increase the time above the MIC, compared to the standard dose of 3.375 g every six hours. Prolonged-infusion dosing is discussed in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/97446.html" rel="external">
          "Prolonged infusions of beta-lactam antibiotics", section on 'Dosing'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H95654635">
         <span class="h2">
          Ceftolozane-tazobactam
         </span>
         <span class="headingEndMark">
          —
         </span>
         Ceftolozane is a cephalosporin whose gram-negative activity is expanded by the addition of tazobactam. The combination has broad-spectrum in vitro activity against aerobic and facultative gram-negative bacilli, including
         <em>
          P. aeruginosa
         </em>
         and most extended-spectrum beta-lactamase (ESBL)-producing Enterobacterales. It has limited gram-positive activity against streptococci. Enterococcal and staphylococcal species are generally resistant. In clinical trials, clinical cure rates with
         <a class="drug drug_general" data-topicid="98763" href="/z/d/drug information/98763.html" rel="external">
          ceftolozane-tazobactam
         </a>
         were similar to those with
         <a class="drug drug_general" data-topicid="9554" href="/z/d/drug information/9554.html" rel="external">
          levofloxacin
         </a>
         for complicated urinary tract infections caused by levofloxacin-susceptible organisms and, when combined with
         <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">
          metronidazole
         </a>
         , were similar to those with
         <a class="drug drug_general" data-topicid="9613" href="/z/d/drug information/9613.html" rel="external">
          meropenem
         </a>
         for complicated intra-abdominal infections [
         <a href="#rid19">
          19-21
         </a>
         ]. In these trials, ceftolozane-tazobactam also performed favorably against infections caused by ESBL-producing isolates [
         <a href="#rid22">
          22
         </a>
         ]. It is also effective in treating carbapenem-resistant, ceftolozane-tazobactam susceptible
         <em>
          P. aeruginosa
         </em>
         pneumonia, as illustrated in a small multicenter, retrospective study [
         <a href="#rid23">
          23
         </a>
         ]. Ceftolozane-tazobactam resulted in comparable clinical cure rates as meropenem for nosocomial pneumonia in mechanically ventilated patients [
         <a href="#rid24">
          24
         </a>
         ]. Efficacy of ceftolozane-tazobactam may be attenuated in patients with renal impairment (estimated glomerular filtration rate [GFR] &lt;50 mL/min).
        </p>
        <p class="headingAnchor" id="H527656792">
         <span class="h2">
          Ceftazidime-avibactam
         </span>
         <span class="headingEndMark">
          —
         </span>
         Avibactam is a novel broad-spectrum beta-lactamase inhibitor that has minimal antibacterial activity on its own. The addition of avibactam to
         <a class="drug drug_general" data-topicid="9226" href="/z/d/drug information/9226.html" rel="external">
          ceftazidime
         </a>
         extends the spectrum of activity to include most Enterobacterales (including those that produce AmpC beta-lactamase, ESBL, and some
         <em>
          K. pneumoniae
         </em>
         and OXA-type carbapenemases) as well as
         <em>
          P. aeruginosa
         </em>
         species with high MICs to ceftazidime alone.
         <a class="drug drug_general" data-topicid="100152" href="/z/d/drug information/100152.html" rel="external">
          Ceftazidime-avibactam
         </a>
         does not have activity against
         <em>
          Acinetobacter
         </em>
         species or organisms that produce metallo-beta-lactamases and is less active against anaerobes than other beta lactam-beta-lactamase combinations [
         <a href="#rid25">
          25
         </a>
         ]. In trials, the microbiological efficacy and clinical cure rates with ceftazidime-avibactam were similar to those with
         <a class="drug drug_general" data-topicid="9613" href="/z/d/drug information/9613.html" rel="external">
          meropenem
         </a>
         for nosocomial pneumonia [
         <a href="#rid26">
          26
         </a>
         ], imipenem-cilastatin for complicated urinary tract infection, and, when combined with
         <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">
          metronidazole
         </a>
         , overall similar to those with meropenem for complicated intra-abdominal infections [
         <a href="#rid27">
          27-29
         </a>
         ]. The microbiological and clinical efficacy of ceftazidime-avibactam against isolates that were not ceftazidime susceptible also compared favorably with that of the carbapenem comparator.
        </p>
        <p class="headingAnchor" id="H1585176709">
         <span class="h2">
          Meropenem-vaborbactam
         </span>
         <span class="headingEndMark">
          —
         </span>
         Vaborbactam is a novel broad-spectrum beta-lactamase inhibitor that potently inhibits class A carbapenemases (including
         <em>
          K. pneumoniae
         </em>
         carbapenemases [KPC]). It is not active against class B or D carbapenemases (ie, metallo-beta-lactamases and OXA-type enzymes). The addition of vaborbactam to
         <a class="drug drug_general" data-topicid="9613" href="/z/d/drug information/9613.html" rel="external">
          meropenem
         </a>
         reduces the MICs of meropenem for class A carbapenemase-producing Enterobacterales to wild-type MIC levels [
         <a href="#rid30">
          30,31
         </a>
         ].
         <a class="drug drug_general" data-topicid="114672" href="/z/d/drug information/114672.html" rel="external">
          Meropenem-vaborbactam
         </a>
         was comparable to
         <a class="drug drug_general" data-topicid="9777" href="/z/d/drug information/9777.html" rel="external">
          piperacillin-tazobactam
         </a>
         in a trial of patients with complicated urinary tract infection [
         <a href="#rid32">
          32
         </a>
         ]. In a small open-label, randomized controlled trial of patients with carbapenem-resistant Enterobacterales (CRE) infections, including bacteremia, hospital-acquired pneumonia including ventilator-associated pneumonia, complicated intra-abdominal infections, and complicated urinary tract infection/pyelonephritis, meropenem-vaborbactam was associated with increased clinical cure, decreased mortality, and decreased nephrotoxicity compared to the best-available therapy [
         <a href="#rid33">
          33
         </a>
         ]. The main role of this agent is for treatment of KPC-producing Enterobacterales.
        </p>
        <p>
         Vaborbactam does not enhance the clinical activity of
         <a class="drug drug_general" data-topicid="9613" href="/z/d/drug information/9613.html" rel="external">
          meropenem
         </a>
         against carbapenem-resistant
         <em>
          P. aeruginosa
         </em>
         or
         <em>
          Acinetobacter
         </em>
         spp.
        </p>
        <p class="headingAnchor" id="H1914663517">
         <span class="h2">
          Imipenem-cilastatin-relebactam
         </span>
         <span class="headingEndMark">
          —
         </span>
         Relebactam is a broad-spectrum beta-lactamase inhibitor that inhibits class A carbapenemases (including KPC). It is not active against class B or D carbapenemases (ie, metallo-beta-lactamases and OXA-type enzymes). The addition of relebactam to imipenem-cilastatin improves the activity against most species of Enterobacterales (reduces the MIC by 2- to 128-fold) and against some imipenem-nonsusceptible
         <em>
          P. aeruginosa
         </em>
         (reduces the MIC eightfold) [
         <a href="#rid34">
          34-36
         </a>
         ]. In clinical trials of patients with complicated urinary tract infections and intraabdominal infections, the efficacy and safety of
         <a class="drug drug_general" data-topicid="121885" href="/z/d/drug information/121885.html" rel="external">
          imipenem-cilastatin-relebactam
         </a>
         were comparable with those of imipenem-cilastatin [
         <a href="#rid37">
          37,38
         </a>
         ]. The main role of this agent is for treatment of KPC-producing Enterobacterales, but clinical data evaluating imipenem-cilastatin-relebactam for such infections are limited [
         <a href="#rid39">
          39
         </a>
         ].
        </p>
        <p>
         Relebactam does not enhance the clinical activity of imipenem-cilastatin against
         <em>
          Acinetobacter
         </em>
         species or
         <em>
          Stenotrophomonas maltophilia
         </em>
         .
        </p>
        <p class="headingAnchor" id="H614341675">
         <span class="h2">
          Sulbactam-durlobactam
         </span>
         <span class="headingEndMark">
          —
         </span>
         Durlobactam, a novel diazabicyclooctane (non-beta lactam) beta-lactamase inhibitor, was developed to treat
         <em>
          Acinetobacter
         </em>
         species in combination with sulbactam and inhibits Class A, C, and D beta-lactamases [
         <a href="#rid3">
          3
         </a>
         ]. In vitro,
         <a class="drug drug_general" data-topicid="141569" href="/z/d/drug information/141569.html" rel="external">
          sulbactam-durlobactam
         </a>
         is highly active against
         <em>
          Acinetobacter baumannii-calcoaceticus
         </em>
         complex [
         <a href="#rid3">
          3
         </a>
         ]. In a large study of 5032 isolates, addition of durlobactam lowered the MIC
         <sub>
          90
         </sub>
         of sulbactam by 32-fold [
         <a href="#rid40">
          40
         </a>
         ]. In the phase 3 ATTACK trial, sulbactam-durlobactam was found to be noninferior for 28-day all-cause mortality compared to
         <a class="drug drug_general" data-topicid="8718" href="/z/d/drug information/8718.html" rel="external">
          colistin
         </a>
         , both drugs in combination with imipenem-cilastatin, for treating serious
         <em>
          Acinetobacter
         </em>
         species infections [
         <a href="#rid41">
          41
         </a>
         ]. It also had a favorable safety profile with decreased incidence of nephrotoxicity compared to colistin. Sulbactam-durlobactam has been approved by the US Food and Drug Administration (FDA) for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by susceptible strains of
         <em>
          Acinetobacter baumannii-calcoaceticus
         </em>
         complex, but it is not yet available in all centers.
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h1">
          CARBAPENEMS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Carbapenems are generally resistant to cleavage by most plasmid and chromosomal beta-lactamases and have a very broad spectrum of activity encompassing [
         <a href="#rid42">
          42,43
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Gram-negative organisms (including beta-lactamase producing
         <em>
          H. influenzae
         </em>
         and
         <em>
          N. gonorrhoeae
         </em>
         , the Enterobacterales, and
         <em>
          P. aeruginosa
         </em>
         ), including those that produce extended-spectrum beta-lactamases
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Anaerobes (including
         <em>
          B. fragilis
         </em>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Gram-positive organisms (including
         <em>
          Enterococcus faecalis
         </em>
         and
         <em>
          Listeria
         </em>
         )
        </p>
        <p>
        </p>
        <p>
         Carbapenems are not generally active against
         <em>
          S. maltophilia
         </em>
         (which has a carbapenem-hydrolyzing chromosomal beta-lactamase),
         <em>
          Burkholderia cepacia
         </em>
         ,
         <em>
          Enterococcus faecium
         </em>
         , oxacillin-resistant staphylococci, or JK diphtheroids.
        </p>
        <p>
         Although initial isolates of
         <em>
          P. aeruginosa
         </em>
         are usually susceptible to the carbapenems, resistance may emerge on therapy when these drugs are used as a single agent. Evidence suggests that carbapenems do not traverse the outer membrane of
         <em>
          P. aeruginosa
         </em>
         through the normal porin channel used by the other beta-lactams but rather through a different channel [
         <a href="#rid44">
          44
         </a>
         ]. Carbapenem-resistant strains of
         <em>
          P. aeruginosa
         </em>
         arising on therapy generally have altered permeability to these drugs and specific changes in their outer membrane proteins or increased expression of efflux pumps; such strains are generally not cross-resistant to other beta-lactams nor do they produce increased or novel beta-lactamase activity.
        </p>
        <p>
         Carbapenem-hydrolyzing beta-lactamases have been increasingly isolated from gram-negative organisms and may limit therapy with these agents in these circumstances. (See
         <a class="medical medical_review" href="/z/d/html/479.html" rel="external">
          "Beta-lactam antibiotics: Mechanisms of action and resistance and adverse effects"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/471.html" rel="external">
          "Carbapenem-resistant
          <i>
           E. coli
          </i>
          ,
          <i>
           K. pneumoniae
          </i>
          , and other Enterobacterales (CRE)"
         </a>
         .)
        </p>
        <p>
         All carbapenems should be dose-reduced in the setting of renal dysfunction  (
         <a class="graphic graphic_table graphicRef51241" href="/z/d/graphic/51241.html" rel="external">
          table 1
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h2">
          Imipenem-cilastatin
         </span>
         <span class="headingEndMark">
          —
         </span>
         Imipenem-cilastatin is inactivated in the proximal renal tubule by the normal human enzyme renal dehydropeptidase I, with resultant low urinary levels of active drug and necrosis of the proximal tubule in the rabbit model. Such cleavage of imipenem-cilastatin is prevented by coadministration of cilastatin, a specific inhibitor of this dehydropeptidase. Imipenem-cilastatin (500 mg IV every six hours with normal renal function) is available for clinical use. The dosing of imipenem-cilastatin should be carefully titrated; patients with creatinine clearance &lt;15 mL/min should generally not receive imipenem-cilastatin unless hemodialysis is ongoing or will start within 48 hours.
        </p>
        <p>
         Imipenem-cilastatin therapy has been associated with central nervous system (CNS) toxicity, including change in mental state, myoclonus, and seizures [
         <a href="#rid45">
          45
         </a>
         ]. In a meta-analysis of over 100 studies that compared imipenem-cilastatin to a non-carbapenem antibiotic, imipenem-cilastatin use was associated with an excess of 4 seizures per 1000 patients treated [
         <a href="#rid46">
          46
         </a>
         ]. CNS toxicity with imipenem-cilastatin is especially evident in patients with underlying CNS disease or impaired renal function. Imipenem-cilastatin should not be used for the therapy of meningitis.
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h2">
          Meropenem
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9613" href="/z/d/drug information/9613.html" rel="external">
          Meropenem
         </a>
         has a spectrum of activity similar to that of imipenem-cilastatin [
         <a href="#rid47">
          47
         </a>
         ]. Unlike imipenem-cilastatin, meropenem is stable to human renal dehydropeptidase I and can be administered without cilastatin. Meropenem may have a slightly lower risk of producing seizures than imipenem-cilastatin, but that decrease was not seen in direct head-to-head comparisons that were limited by small sample size [
         <a href="#rid46">
          46
         </a>
         ]. Meropenem is useful for the treatment of bacterial meningitis (in pediatric patients &gt;3 months old) and intra-abdominal infection [
         <a href="#rid48">
          48,49
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h2">
          Ertapenem
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="8675" href="/z/d/drug information/8675.html" rel="external">
          Ertapenem
         </a>
         has a narrower spectrum of activity than imipenem-cilastatin or
         <a class="drug drug_general" data-topicid="9613" href="/z/d/drug information/9613.html" rel="external">
          meropenem
         </a>
         . It is active against most Enterobacterales and anaerobes but less active than the other carbapenems for
         <em>
          P. aeruginosa
         </em>
         ,
         <em>
          Acinetobacter
         </em>
         , and gram-positive bacteria, particularly enterococci and penicillin-resistant pneumococci. The major benefit of ertapenem over other carbapenems is that it has a long half-life and can be administered once daily. Unlike meropenem, there are insufficient data to support the use of ertapenem for the therapy of meningitis.
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h2">
          Doripenem
         </span>
         <span class="headingEndMark">
          —
         </span>
         Doripenem has demonstrated clinical efficacy in the treatment of complicated urinary tract and intra-abdominal infections [
         <a href="#rid50">
          50,51
         </a>
         ]. It has a similar overall spectrum of activity as that of
         <a class="drug drug_general" data-topicid="9613" href="/z/d/drug information/9613.html" rel="external">
          meropenem
         </a>
         but has somewhat greater in vitro activity against
         <em>
          P. aeruginosa
         </em>
         [
         <a href="#rid52">
          52,53
         </a>
         ].
        </p>
        <p>
         In 2014, the US Food and Drug Administration (FDA) approved revisions to the doripenem label warning clinicians about increased mortality rates in patients with ventilator-associated bacterial pneumonia who received doripenem rather than imipenem-cilastatin, based on results of a randomized trial that was stopped early due to safety concerns [
         <a href="#rid54">
          54
         </a>
         ]. In the trial, 28-day all-cause mortality was higher and clinical response rates were lower with doripenem compared with imipenem-cilastatin, although different dosing regimens and use of adjunctive aminoglycosides may have influenced these results [
         <a href="#rid55">
          55
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6993.html" rel="external">
          "Treatment of hospital-acquired and ventilator-associated pneumonia in adults", section on 'Gram-negative pathogens'
         </a>
         .)
        </p>
        <p>
         Further clinical trials are required to establish the efficacy and safety of doripenem in the setting of bacteremia and other severe infections.
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h1">
          MONOBACTAMS (AZTREONAM)
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9047" href="/z/d/drug information/9047.html" rel="external">
          Aztreonam
         </a>
         is a monocyclic beta-lactam antibiotic with good in vitro activity against the majority of gram-negative aerobic and facultative bacteria, including the Enterobacterales and
         <em>
          P. aeruginosa
         </em>
         [
         <a href="#rid43">
          43,56
         </a>
         ]. It has virtually no activity against gram-positive organisms or anaerobes; the majority of strains of
         <em>
          Acinetobacter
         </em>
         and
         <em>
          S. maltophilia
         </em>
         are resistant, and resistant strains of
         <em>
          P. aeruginosa
         </em>
         frequently emerge during therapy with aztreonam alone. The spectrum of activity of aztreonam is similar to that of the aminoglycosides. It is, however, less reliable therapy than aminoglycosides for the non-enteric gram-negative bacilli, such as
         <em>
          Acinetobacter
         </em>
         ,
         <em>
          P. aeruginosa
         </em>
         , and
         <em>
          S. maltophilia
         </em>
         .
        </p>
        <p>
         <a class="drug drug_general" data-topicid="9047" href="/z/d/drug information/9047.html" rel="external">
          Aztreonam
         </a>
         is distinctive in that it is not degraded by the class B metallo-beta-lactamases, such as New Delhi metallo-beta-lactamase. (See
         <a class="medical medical_review" href="/z/d/html/471.html" rel="external">
          "Carbapenem-resistant
          <i>
           E. coli
          </i>
          ,
          <i>
           K. pneumoniae
          </i>
          , and other Enterobacterales (CRE)", section on 'Classifications and geographic distribution'
         </a>
         .)
        </p>
        <p>
         Data support the absence of cross-allergenicity between
         <a class="drug drug_general" data-topicid="9047" href="/z/d/drug information/9047.html" rel="external">
          aztreonam
         </a>
         and other beta-lactam antibiotics [
         <a href="#rid57">
          57
         </a>
         ]. Patients with
         <a class="drug drug_general" data-topicid="9226" href="/z/d/drug information/9226.html" rel="external">
          ceftazidime
         </a>
         allergy, however, may be allergic to aztreonam because of a shared side chain. The clinical situation in which aztreonam is most useful is in place of an extended-spectrum penicillin or cephalosporin when these are indicated but cannot be used because of severe allergy. Aztreonam is the only monobactam currently marketed. Dose reductions are recommended in the setting of renal dysfunction  (
         <a class="graphic graphic_table graphicRef51241" href="/z/d/graphic/51241.html" rel="external">
          table 1
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H57683482">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical terminology.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topic (see
         <a class="medical medical_basics" href="/z/d/html/138962.html" rel="external">
          "Patient education: Carbapenem-resistant enterobacterales (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Combination beta-lactamase inhibitors
         </strong>
         – Clavulanate, sulbactam, tazobactam, avibactam, vaborbactam, relebactam, and durlobactam are beta-lactamase inhibitors that have little intrinsic antibacterial activity but inhibit the activity of a number of plasmid-mediated beta-lactamases. Combination of one of these agents with
         <a class="drug drug_general" data-topicid="8737" href="/z/d/drug information/8737.html" rel="external">
          ampicillin
         </a>
         ,
         <a class="drug drug_general" data-topicid="8673" href="/z/d/drug information/8673.html" rel="external">
          amoxicillin
         </a>
         ,
         <a class="drug drug_general" data-topicid="9775" href="/z/d/drug information/9775.html" rel="external">
          piperacillin
         </a>
         , ceftolozane, or
         <a class="drug drug_general" data-topicid="9226" href="/z/d/drug information/9226.html" rel="external">
          ceftazidime
         </a>
         results in antibiotics with an enhanced spectrum of activity against many, but not all, organisms containing plasmid-mediated beta-lactamases. The addition of avibactam to ceftazidime, vaborbactam to
         <a class="drug drug_general" data-topicid="9613" href="/z/d/drug information/9613.html" rel="external">
          meropenem
         </a>
         , and relebactam to imipenem-cilastatin results in enhanced activity against many, but not all, organisms producing carbapenemases. The sulbactam component of
         <a class="drug drug_general" data-topicid="8745" href="/z/d/drug information/8745.html" rel="external">
          ampicillin-sulbactam
         </a>
         has activity against
         <em>
          Acinetobacter
         </em>
         , as does the new combination
         <a class="drug drug_general" data-topicid="141569" href="/z/d/drug information/141569.html" rel="external">
          sulbactam-durlobactam
         </a>
         . (See
         <a class="local">
          'Beta-lactamase inhibitor combinations'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Carbapenems
         </strong>
         – Carbapenems have a broad spectrum of activity against gram-negative organisms (including those that produce extended spectrum beta-lactamases), anaerobes (including
         <em>
          Bacteroides fragilis
         </em>
         ), and gram-positive organisms (including
         <em>
          Enterococcus faecalis
         </em>
         and
         <em>
          Listeria
         </em>
         ). When carbapenems are used as a single agent against initially susceptible isolates of
         <em>
          Pseudomonas aeruginosa
         </em>
         , resistance may emerge during therapy. (See
         <a class="local">
          'Carbapenems'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Aztreonam
         </strong>
         – Aztreonam is a monocyclic beta-lactam with good in vitro activity against the majority of gram-negative aerobic and facultative bacteria, including the Enterobacterales and
         <em>
          P. aeruginosa
         </em>
         , but virtually no activity against gram-positive organisms or anaerobes. However, when used alone for therapy of
         <em>
          P.
         </em>
         <em>
          aeruginosa
         </em>
         infection, resistance may emerge. Aztreonam has minimal cross-allergenicity with other beta-lactams with the exception of
         <a class="drug drug_general" data-topicid="9226" href="/z/d/drug information/9226.html" rel="external">
          ceftazidime
         </a>
         . (See
         <a class="local">
          'Monobactams (aztreonam)'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Dosing
         </strong>
         – The dosing of these novel beta-lactams and dose modifications in patients with renal dysfunction  (
         <a class="graphic graphic_table graphicRef51241" href="/z/d/graphic/51241.html" rel="external">
          table 1
         </a>
         ) are important considerations in prescribing these drugs.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Bush LM, Johnson CC. Ureidopenicillins and beta-lactam/beta-lactamase inhibitor combinations. Infect Dis Clin North Am 2000; 14:409.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yahav D, Giske CG, Grāmatniece A, et al. New β-Lactam-β-Lactamase Inhibitor Combinations. Clin Microbiol Rev 2020; 34.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Papp-Wallace KM, McLeod SM, Miller AA. Durlobactam, a Broad-Spectrum Serine β-lactamase Inhibitor, Restores Sulbactam Activity Against Acinetobacter Species. Clin Infect Dis 2023; 76:S194.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sensakovic JW, Smith LG. Beta-lactamase inhibitor combinations. Med Clin North Am 1995; 79:695.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lodise TP Jr, Lomaestro B, Drusano GL. Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy. Clin Infect Dis 2007; 44:357.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Falagas ME, Tansarli GS, Ikawa K, Vardakas KZ. Clinical outcomes with extended or continuous versus short-term intravenous infusion of carbapenems and piperacillin/tazobactam: a systematic review and meta-analysis. Clin Infect Dis 2013; 56:272.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Monti G, Bradic N, Marzaroli M, et al. Continuous vs Intermittent Meropenem Administration in Critically Ill Patients With Sepsis: The MERCY Randomized Clinical Trial. JAMA 2023; 330:141.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Calver AD, Walsh NS, Quinn PF, et al. Dosing of amoxicillin/clavulanate given every 12 hours is as effective as dosing every 8 hours for treatment of lower respiratory tract infection. Lower Respiratory Tract Infection Collaborative Study Group. Clin Infect Dis 1997; 24:570.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McKinnon PS, Paladino JA, Grayson ML, et al. Cost-effectiveness of ampicillin/sulbactam versus imipenem/cilastatin in the treatment of limb-threatening foot infections in diabetic patients. Clin Infect Dis 1997; 24:57.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Messick CR, Mamdani M, McNicholl IR, et al. Pharmacoeconomic analysis of ampicillin-sulbactam versus cefoxitin in the treatment of intraabdominal infections. Pharmacotherapy 1998; 18:175.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Paladino JA, Rainstein MA, Serrianne DJ, et al. Ampicillin-sulbactam versus cefoxitin for prophylaxis in high-risk patients undergoing abdominal surgery. Pharmacotherapy 1994; 14:734.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liu CY, Huang YT, Liao CH, et al. Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. Antimicrob Agents Chemother 2008; 52:3161.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hoban DJ, Bouchillon SK, Hawser SP, et al. Susceptibility of gram-negative pathogens isolated from patients with complicated intra-abdominal infections in the United States, 2007-2008: results of the Study for Monitoring Antimicrobial Resistance Trends (SMART). Antimicrob Agents Chemother 2010; 54:3031.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hsueh PR, Badal RE, Hawser SP, et al. Epidemiology and antimicrobial susceptibility profiles of aerobic and facultative Gram-negative bacilli isolated from patients with intra-abdominal infections in the Asia-Pacific region: 2008 results from SMART (Study for Monitoring Antimicrobial Resistance Trends). Int J Antimicrob Agents 2010; 36:408.
          </a>
         </li>
         <li class="breakAll">
          Unasyn (oral). International prescribing information. New York, NY: Pfizer Inc; 2012.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Friedel HA, Campoli-Richards DM, Goa KL. Sultamicillin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs 1989; 37:491.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lode H. Role of sultamicillin and ampicillin/sulbactam in the treatment of upper and lower bacterial respiratory tract infections. Int J Antimicrob Agents 2001; 18:199.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sanders WE Jr, Sanders CC. Piperacillin/tazobactam: a critical review of the evolving clinical literature. Clin Infect Dis 1996; 22:107.
          </a>
         </li>
         <li class="breakAll">
          Zerbaxa (ceftolozane/tazobactam). US FDA approved product information. National Library of Medicine. www.dailymed.nlm.nih.gov (Accessed on January 08, 2015).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wagenlehner FM, Umeh O, Steenbergen J, et al. Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI). Lancet 2015; 385:1949.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Solomkin J, Hershberger E, Miller B, et al. Ceftolozane/Tazobactam Plus Metronidazole for Complicated Intra-abdominal Infections in an Era of Multidrug Resistance: Results From a Randomized, Double-Blind, Phase 3 Trial (ASPECT-cIAI). Clin Infect Dis 2015; 60:1462.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Popejoy MW, Paterson DL, Cloutier D, et al. Efficacy of ceftolozane/tazobactam against urinary tract and intra-abdominal infections caused by ESBL-producing Escherichia coli and Klebsiella pneumoniae: a pooled analysis of Phase 3 clinical trials. J Antimicrob Chemother 2017; 72:268.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Munita JM, Aitken SL, Miller WR, et al. Multicenter Evaluation of Ceftolozane/Tazobactam for Serious Infections Caused by Carbapenem-Resistant Pseudomonas aeruginosa. Clin Infect Dis 2017.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kollef MH, Nováček M, Kivistik Ü, et al. Ceftolozane-tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trial. Lancet Infect Dis 2019; 19:1299.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhanel GG, Lawson CD, Adam H, et al. Ceftazidime-avibactam: a novel cephalosporin/β-lactamase inhibitor combination. Drugs 2013; 73:159.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Torres A, Zhong N, Pachl J, et al. Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial. Lancet Infect Dis 2018; 18:285.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mazuski JE, Gasink LB, Armstrong J, et al. Efficacy and Safety of Ceftazidime-Avibactam Plus Metronidazole Versus Meropenem in the Treatment of Complicated Intra-abdominal Infection: Results From a Randomized, Controlled, Double-Blind, Phase 3 Program. Clin Infect Dis 2016; 62:1380.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vazquez JA, González Patzán LD, Stricklin D, et al. Efficacy and safety of ceftazidime-avibactam versus imipenem-cilastatin in the treatment of complicated urinary tract infections, including acute pyelonephritis, in hospitalized adults: results of a prospective, investigator-blinded, randomized study. Curr Med Res Opin 2012; 28:1921.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carmeli Y, Armstrong J, Laud PJ, et al. Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study. Lancet Infect Dis 2016; 16:661.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lomovskaya O, Sun D, Rubio-Aparicio D, et al. Vaborbactam: Spectrum of Beta-Lactamase Inhibition and Impact of Resistance Mechanisms on Activity in Enterobacteriaceae. Antimicrob Agents Chemother 2017; 61.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Castanheira M, Huband MD, Mendes RE, Flamm RK. Meropenem-Vaborbactam Tested against Contemporary Gram-Negative Isolates Collected Worldwide during 2014, Including Carbapenem-Resistant, KPC-Producing, Multidrug-Resistant, and Extensively Drug-Resistant Enterobacteriaceae. Antimicrob Agents Chemother 2017; 61.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kaye KS, Bhowmick T, Metallidis S, et al. Effect of Meropenem-Vaborbactam vs Piperacillin-Tazobactam on Clinical Cure or Improvement and Microbial Eradication in Complicated Urinary Tract Infection: The TANGO I Randomized Clinical Trial. JAMA 2018; 319:788.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wunderink RG, Giamarellos-Bourboulis EJ, Rahav G, et al. Effect and Safety of Meropenem-Vaborbactam versus Best-Available Therapy in Patients with Carbapenem-Resistant Enterobacteriaceae Infections: The TANGO II Randomized Clinical Trial. Infect Dis Ther 2018; 7:439.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schmidt-Malan SM, Mishra AJ, Mushtaq A, et al. In Vitro Activity of Imipenem-Relebactam and Ceftolozane-Tazobactam against Resistant Gram-Negative Bacilli. Antimicrob Agents Chemother 2018; 62.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Young K, Painter RE, Raghoobar SL, et al. In vitro studies evaluating the activity of imipenem in combination with relebactam against Pseudomonas aeruginosa. BMC Microbiol 2019; 19:150.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhanel GG, Lawrence CK, Adam H, et al. Imipenem-Relebactam and Meropenem-Vaborbactam: Two Novel Carbapenem-β-Lactamase Inhibitor Combinations. Drugs 2018; 78:65.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sims M, Mariyanovski V, McLeroth P, et al. Prospective, randomized, double-blind, Phase 2 dose-ranging study comparing efficacy and safety of imipenem/cilastatin plus relebactam with imipenem/cilastatin alone in patients with complicated urinary tract infections. J Antimicrob Chemother 2017; 72:2616.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lucasti C, Vasile L, Sandesc D, et al. Phase 2, Dose-Ranging Study of Relebactam with Imipenem-Cilastatin in Subjects with Complicated Intra-abdominal Infection. Antimicrob Agents Chemother 2016; 60:6234.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Motsch J, Murta de Oliveira C, Stus V, et al. RESTORE-IMI 1: A Multicenter, Randomized, Double-blind Trial Comparing Efficacy and Safety of Imipenem/Relebactam vs Colistin Plus Imipenem in Patients With Imipenem-nonsusceptible Bacterial Infections. Clin Infect Dis 2020; 70:1799.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Karlowsky JA, Hackel MA, McLeod SM, Miller AA. In Vitro Activity of Sulbactam-Durlobactam against Global Isolates of Acinetobacter baumannii-calcoaceticus Complex Collected from 2016 to 2021. Antimicrob Agents Chemother 2022; 66:e0078122.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kaye KS, Shorr AF, Wunderink RG, et al. Efficacy and safety of sulbactam-durlobactam versus colistin for the treatment of patients with serious infections caused by Acinetobacter baumannii-calcoaceticus complex: a multicentre, randomised, active-controlled, phase 3, non-inferiority clinical trial (ATTACK). Lancet Infect Dis 2023; 23:1072.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Norrby SR. Carbapenems. Med Clin North Am 1995; 79:745.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Asbel LE, Levison ME. Cephalosporins, carbapenems, and monobactams. Infect Dis Clin North Am 2000; 14:435.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Huang H, Hancock RE. Genetic definition of the substrate selectivity of outer membrane porin protein OprD of Pseudomonas aeruginosa. J Bacteriol 1993; 175:7793.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Calandra G, Lydick E, Carrigan J, et al. Factors predisposing to seizures in seriously ill infected patients receiving antibiotics: experience with imipenem/cilastatin. Am J Med 1988; 84:911.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cannon JP, Lee TA, Clark NM, et al. The risk of seizures among the carbapenems: a meta-analysis. J Antimicrob Chemother 2014; 69:2043.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cox CE, Holloway WJ, Geckler RW. A multicenter comparative study of meropenem and imipenem/cilastatin in the treatment of complicated urinary tract infections in hospitalized patients. Clin Infect Dis 1995; 21:86.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Condon RE, Walker AP, Sirinek KR, et al. Meropenem versus tobramycin plus clindamycin for treatment of intraabdominal infections: results of a prospective, randomized, double-blind clinical trial. Clin Infect Dis 1995; 21:544.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chang DC, Wilson SE. Meta-analysis of the clinical outcome of carbapenem monotherapy in the adjunctive treatment of intra-abdominal infections. Am J Surg 1997; 174:284.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Naber KG, Llorens L, Kaniga K, et al. Intravenous doripenem at 500 milligrams versus levofloxacin at 250 milligrams, with an option to switch to oral therapy, for treatment of complicated lower urinary tract infection and pyelonephritis. Antimicrob Agents Chemother 2009; 53:3782.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lucasti C, Jasovich A, Umeh O, et al. Efficacy and tolerability of IV doripenem versus meropenem in adults with complicated intra-abdominal infection: a phase III, prospective, multicenter, randomized, double-blind, noninferiority study. Clin Ther 2008; 30:868.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhanel GG, Wiebe R, Dilay L, et al. Comparative review of the carbapenems. Drugs 2007; 67:1027.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Paterson DL, Depestel DD. Doripenem. Clin Infect Dis 2009; 49:291.
          </a>
         </li>
         <li class="breakAll">
          US Food and Drug Administration. FDA approves label changes for antibacterial Doribax (doripenem) describing increased risk of death for ventilator patients with pneumonia. http://www.fda.gov/Drugs/DrugSafety/ucm387971.htm (Accessed on March 10, 2014).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kollef MH, Chastre J, Clavel M, et al. A randomized trial of 7-day doripenem versus 10-day imipenem-cilastatin for ventilator-associated pneumonia. Crit Care 2012; 16:R218.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Johnson DH, Cunha BA. Aztreonam. Med Clin North Am 1995; 79:733.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kishiyama JL, Adelman DC. The cross-reactivity and immunology of beta-lactam antibiotics. Drug Saf 1994; 10:318.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 482 Version 34.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10829263" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Ureidopenicillins and beta-lactam/beta-lactamase inhibitor combinations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33177185" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Newβ-Lactam-β-Lactamase Inhibitor Combinations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37125470" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Durlobactam, a Broad-Spectrum Serineβ-lactamase Inhibitor, Restores Sulbactam Activity Against Acinetobacter Species.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7791417" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Beta-lactamase inhibitor combinations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17205441" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23074314" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Clinical outcomes with extended or continuous versus short-term intravenous infusion of carbapenems and piperacillin/tazobactam: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37326473" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Continuous vs Intermittent Meropenem Administration in Critically Ill Patients With Sepsis: The MERCY Randomized Clinical Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9145729" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Dosing of amoxicillin/clavulanate given every 12 hours is as effective as dosing every 8 hours for treatment of lower respiratory tract infection. Lower Respiratory Tract Infection Collaborative Study Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8994756" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Cost-effectiveness of ampicillin/sulbactam versus imipenem/cilastatin in the treatment of limb-threatening foot infections in diabetic patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9469691" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Pharmacoeconomic analysis of ampicillin-sulbactam versus cefoxitin in the treatment of intraabdominal infections.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7885978" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Ampicillin-sulbactam versus cefoxitin for prophylaxis in high-risk patients undergoing abdominal surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18625771" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20457818" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Susceptibility of gram-negative pathogens isolated from patients with complicated intra-abdominal infections in the United States, 2007-2008: results of the Study for Monitoring Antimicrobial Resistance Trends (SMART).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20728316" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Epidemiology and antimicrobial susceptibility profiles of aerobic and facultative Gram-negative bacilli isolated from patients with intra-abdominal infections in the Asia-Pacific region: 2008 results from SMART (Study for Monitoring Antimicrobial Resistance Trends).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20728316" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Epidemiology and antimicrobial susceptibility profiles of aerobic and facultative Gram-negative bacilli isolated from patients with intra-abdominal infections in the Asia-Pacific region: 2008 results from SMART (Study for Monitoring Antimicrobial Resistance Trends).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2661196" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Sultamicillin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11673031" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Role of sultamicillin and ampicillin/sulbactam in the treatment of upper and lower bacterial respiratory tract infections.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8824974" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Piperacillin/tazobactam: a critical review of the evolving clinical literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8824974" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Piperacillin/tazobactam: a critical review of the evolving clinical literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25931244" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25670823" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Ceftolozane/Tazobactam Plus Metronidazole for Complicated Intra-abdominal Infections in an Era of Multidrug Resistance: Results From a Randomized, Double-Blind, Phase 3 Trial (ASPECT-cIAI).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27707990" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Efficacy of ceftolozane/tazobactam against urinary tract and intra-abdominal infections caused by ESBL-producing Escherichia coli and Klebsiella pneumoniae: a pooled analysis of Phase 3 clinical trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28329350" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Multicenter Evaluation of Ceftolozane/Tazobactam for Serious Infections Caused by Carbapenem-Resistant Pseudomonas aeruginosa.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31563344" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Ceftolozane-tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23371303" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Ceftazidime-avibactam: a novel cephalosporin/β-lactamase inhibitor combination.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29254862" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26962078" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Efficacy and Safety of Ceftazidime-Avibactam Plus Metronidazole Versus Meropenem in the Treatment of Complicated Intra-abdominal Infection: Results From a Randomized, Controlled, Double-Blind, Phase 3 Program.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23145859" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Efficacy and safety of ceftazidime-avibactam versus imipenem-cilastatin in the treatment of complicated urinary tract infections, including acute pyelonephritis, in hospitalized adults: results of a prospective, investigator-blinded, randomized study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27107460" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28848018" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Vaborbactam: Spectrum of Beta-Lactamase Inhibition and Impact of Resistance Mechanisms on Activity in Enterobacteriaceae.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28652234" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Meropenem-Vaborbactam Tested against Contemporary Gram-Negative Isolates Collected Worldwide during 2014, Including Carbapenem-Resistant, KPC-Producing, Multidrug-Resistant, and Extensively Drug-Resistant Enterobacteriaceae.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29486041" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Effect of Meropenem-Vaborbactam vs Piperacillin-Tazobactam on Clinical Cure or Improvement and Microbial Eradication in Complicated Urinary Tract Infection: The TANGO I Randomized Clinical Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30270406" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Effect and Safety of Meropenem-Vaborbactam versus Best-Available Therapy in Patients with Carbapenem-Resistant Enterobacteriaceae Infections: The TANGO II Randomized Clinical Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29760145" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : In Vitro Activity of Imipenem-Relebactam and Ceftolozane-Tazobactam against Resistant Gram-Negative Bacilli.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31272373" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : In vitro studies evaluating the activity of imipenem in combination with relebactam against Pseudomonas aeruginosa.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29230684" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Imipenem-Relebactam and Meropenem-Vaborbactam: Two Novel Carbapenem-β-Lactamase Inhibitor Combinations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28575389" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Prospective, randomized, double-blind, Phase 2 dose-ranging study comparing efficacy and safety of imipenem/cilastatin plus relebactam with imipenem/cilastatin alone in patients with complicated urinary tract infections.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27503659" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Phase 2, Dose-Ranging Study of Relebactam with Imipenem-Cilastatin in Subjects with Complicated Intra-abdominal Infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31400759" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : RESTORE-IMI 1: A Multicenter, Randomized, Double-blind Trial Comparing Efficacy and Safety of Imipenem/Relebactam vs Colistin Plus Imipenem in Patients With Imipenem-nonsusceptible Bacterial Infections.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36005804" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : In Vitro Activity of Sulbactam-Durlobactam against Global Isolates of Acinetobacter baumannii-calcoaceticus Complex Collected from 2016 to 2021.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37182534" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Efficacy and safety of sulbactam-durlobactam versus colistin for the treatment of patients with serious infections caused by Acinetobacter baumannii-calcoaceticus complex: a multicentre, randomised, active-controlled, phase 3, non-inferiority clinical trial (ATTACK).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7791421" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Carbapenems.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10829264" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Cephalosporins, carbapenems, and monobactams.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8253668" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Genetic definition of the substrate selectivity of outer membrane porin protein OprD of Pseudomonas aeruginosa.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3284342" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Factors predisposing to seizures in seriously ill infected patients receiving antibiotics: experience with imipenem/cilastatin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24744302" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : The risk of seizures among the carbapenems: a meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7578765" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : A multicenter comparative study of meropenem and imipenem/cilastatin in the treatment of complicated urinary tract infections in hospitalized patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8527541" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Meropenem versus tobramycin plus clindamycin for treatment of intraabdominal infections: results of a prospective, randomized, double-blind clinical trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9324138" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Meta-analysis of the clinical outcome of carbapenem monotherapy in the adjunctive treatment of intra-abdominal infections.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19581455" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Intravenous doripenem at 500 milligrams versus levofloxacin at 250 milligrams, with an option to switch to oral therapy, for treatment of complicated lower urinary tract infection and pyelonephritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18555934" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Efficacy and tolerability of IV doripenem versus meropenem in adults with complicated intra-abdominal infection: a phase III, prospective, multicenter, randomized, double-blind, noninferiority study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17488146" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Comparative review of the carbapenems.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19527173" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Doripenem.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19527173" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Doripenem.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23148736" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : A randomized trial of 7-day doripenem versus 10-day imipenem-cilastatin for ventilator-associated pneumonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7791420" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Aztreonam.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8018304" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : The cross-reactivity and immunology of beta-lactam antibiotics.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
